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Abstract
Radiotracers incorporating the urea-based Glu-NH-C(O)-NH-Lys group have gained prominence due to their role in targeting
prostate-specific membrane antigen (PSMA)—a clinical biomarker of prostate cancer. Here, the synthesis, radiolabeling, and in
vitro and in vivo characterization of two 68Ga-radiolabeled Glu-NH-C(O)-NH-Lys radiotracers conjugated to the desferriox-
amine B (DFO) chelate were evaluated. Two linker groups based on amide bond and thiourea coupling chemistries were
employed to develop 68Ga-DFO-Nsucc-PSMA (68Ga-4) and 68Ga-DFO-pNCS-Bn-PSMA (68Ga-7), respectively. Radiosynthesis
proceeded quantitatively at room temperature with high radiochemical yields, chemical/radiochemical purities, and specific
activities. Pharmacokinetic profiles of 68Ga-4 and 68Ga-7 were assessed using positron-emission tomography (PET) in mice
bearing subcutaneous LNCaP tumors. Data were compared to the current clinical benchmark radiotracer 68Ga-HBED-CC-PSMA
(68Ga-1) (HBED ¼ N,N0-Bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N0-diacetic acid). Results indicated
that the target binding affinity, protein association, blood pool and background organ clearance properties, and uptake in PSMA-
positive lesions are strongly dependent on the nature of the chelate, the linker, and the spacer groups. Protein dissociation
constants (Kd values) were found to be predictive of pharmacokinetics in vivo. Compared to
68Ga-1, 68Ga-4 and 68Ga-7 resulted in
decreased tumor uptake but enhanced blood pool clearance and reduced residence time in the kidney. The study highlights the
importance of maximizing protein binding affinity during radiotracer optimization.
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Introduction
Prostate-specific membrane antigen (PSMA; also known as
glutamate carboxypeptidase II [GCPII] or N-acetyl-L-aspar-
tyl-L-glutamate peptidase I [NAALADase I]) is an important
class II membrane-bound zinc metalloenzyme that catalyzes
the hydrolysis of N-acetylaspartylglutamate (NAAG) to gluta-
mate and N-acetylaspatate (NAA).1 The PSMA has emerged as
a valuable preclinical and clinical biomarker of prostate cancer
(PCa). Many prostate cancers, as well as other cancers that
exhibit neoangiogenesis, express high levels of PSMA. Lower
levels are found in physiologically normal tissues such as the
kidneys, salivary glands, and small intestine.2 Consequently,
differential PSMA expression in PCa has led physicians and
radiochemists to explore the use of PSMA as a target for deli-
vering a wide range of diagnostic and radiotherapeutic
nuclides.3-5
Worldwide, at least 50 clinical trials have investigated
PSMA-targeted imaging or therapy in different populations
of patients with PCa (source: www.clinicaltrials.gov). The
two most important classes of drugs targeting PSMA are
small-molecule urea-based inhibitors4,6-12 and anti-PSMA
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antibodies.13-18 In terms of molecular imaging with
positron-emission tomography (PET), the urea-based 68Ga-
HBED-CC-PSMA19-24 (68Ga-1; Figure 1) and antibody-based
89Zr-DFO-J59115-18 have shown promise for characterizing
PSMA profiles in humans. For small-molecule PSMA inhibi-
tors, the excellent clinical performance of 68Ga-labeled agents
for PET also prompted multicenter studies which demonstrated
that 177Lu-labeled analogues can be used to advance a novel
“theranostic” (combined diagnostic imaging and radiotherapy)
regimen.25,26
The synthesis and biological evaluation of a large number of
Glu-NH-C(O)-NH-Lys inhibitors of PSMA have been
reported.6,27 Many radiolabeled analogues are also studied in
vivo. Selected examples include work using the radionuclides
fluorine-18,28-31 copper-64,11,32 gallium-68,19,20,23,33 techne-
tium .99m,7,9,34 and various radiohalogens.4,6,35 While recent
studies have demonstrated that the performance of at least two
18F-radiolabeled agents,18F-DCFPyL23 and 18F-PSMA-6,24
and the more recent compound 18F-PSMA-1007,36 compare
favorably to that of 68Ga-1; this 68Ga-radiotracer remains the
most well-characterized radiometal-based agent for PET ima-
ging of PSMA. The radiosynthesis of 68Ga-1 is well estab-
lished—essentially quantitative radiolabeling can be achieved
upon reacting the precursor HBED-CC-PSMA (compound 1)
with 68Ga in sodium acetate buffer at pH 4.5 for 10 minutes at
95C.19,20 Interestingly, the use of the HBED chelate has been
suggested to lead to the potential formation of two diastereo-
mers as resolved by high-performance liquid chromatography
(HPLC).20 The composition ratio of these two species depends
on the pH and reaction temperature—data confirming that one
isomer is thermodynamically more stable in aqueous solution
and that intramolecular hydrogen bonding is likely to influence
complex stability. Experimental studies in cells also showed
that the two species have identical binding properties toward
PSMA.20 However, the formation of two isomers (in a variable
ratio20) is unsatisfactory from the perspective of quality control
(QC) in a clinical setting.
In this work, we synthesized and evaluated two new 68Ga-
labeled PSMA inhibitors bearing the tris-hydroxamic acid che-
late desferrioxamine B (DFO). Two bifunctional versions of
DFO (DFO-Nsucc [2] and DFO-pNCS-Bn [5]; Figure 2) with
varying lipophilic character of the linker/spacer group were
conjugated to Glu-NH-C(O)-NH-Lys-Ahx starting materials
(compounds 3 and 6) to generate the radiolabeling precursors
4 and 7, respectively (Figure 2). Saturation binding assays in
LNCaP cells, ex vivo protein binding and stability measure-
ments, and PET imaging were used to compare the two new
radiotracers 68Ga-DFO-Nsucc-PSMA (68Ga-4) and 68Ga-DFO-
pNCS-Bn-PSMA (68Ga-7), to the clinical radiotracer 68Ga-1.
Results found that targeting of PSMA using urea-based radio-
metal complexes is highly sensitive to the chemical nature of
the chelate and linker/spacer groups.
Materials and Methods
Standard laboratory techniques were employed throughout.
Unless otherwise stated, all solvents and reagents were
used as received from the supplier (SigmaAldrich [Darmstadt,
Germany], TCI Deutschland [Eschborn, Germany], Acros
[Geel, Belgium]). The HBED-CC-PSMA (also known as
DKFZ-11) was purchased from ABX (Radeberg, Germany).
Low-resolution electrospray ionization mass spectrometry
((þ)-LR-ESI-MS) was performed on a PerkinElmer Flexar
SQ 300 MS Detector (Waltham, MA). High-resolution electro-
spray ionization mass spectra ((þ)-HR-ESI-MS) were mea-
sured by the Mass Spectrometry Service at the University of
Zurich. HPLC was conducted on an Agilent 1260 Infinity Sys-
tem equipped with an Agilent 1200 DAD UV detector (UV
detection at 220 nm) (Santa Clara, CA) equipped with Raytest
radiation detector (Raytest GmbH, Straubenhardt, Germany)
and a Chromolith Performance RP-18e 100-4.6 mm column
(Merck, Billerica, MA). Typically, a water/acetonitrile gradient
elution method (1.0 mL/min; 5 minutes; 5%-60% MeCN; UV
detection at 220 nm and 320 nm) was used for analytical mea-
surements (Chromolith method). Samples were lyophilized
using a Christ Alpha 1-2 LD plus lyophilizer. All instruments
measuring radioactivity were calibrated and maintained in
accordance with previously reported routine QC procedures.37
Radioactivity measurements were made using a calibrated
Activimeter ISOMED 2010 (Nuklear-Medizintechnik, Dres-
den, Germany). For accurate quantification of radioactivity,
experimental samples were counted for between 30 seconds
Figure 1. Structure of the HBED-CC- prostate-specific membrane antigen (PSMA) ligand (compound 1).
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and 1 minute on a calibrated PerkinElmer 2480 Automatic
Wizard2 Gamma Counter (Perkin Elmer, Waltham, Massachu-
setts). A dynamic energy window of 400 to 600 keV was used
for 68 Ga (511 keV emission) detection.
Synthesis
TheDFO-Nsucc-PSMA (4). The DFO was reacted with succinic
anhydride in accordance with previously reported methods to
give the reagent DFO-Nsucc (2).38 The tris-tBu-protected urea
(3) was purchased from ABX and used as received. The tris-
tBu-protected urea (3; 5.2 mg, molecular weight [MW] 600.8
g/mol, 9.07 mmol) was dissolved in DMF (200 mL). DFO-
Nsucc (2; 6.60 mg, MW 661.7 g/mol, 10.0 mmol) is only spar-
ingly soluble in DMF and was dissolved in dimethyl sulfoxide
(DMSO; 200 mL). 1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate
(HATU; 4.0 mg, 1.16 equivalent) was dissolved in DMF
(200 mL) to which N, N-diisopropylethylamine (DIPEA; 3.3
mL, 1.9 mmol, 2.1 equivalent) was added. The HATU/DIPEA
mixture was added to the solution of compound 2 and then the
resulting mixture was added to the solution of compound 3. The
reaction was stirred at room temperature for 24 hours and
progress was monitored by (þ)-LR-ESI-MS. Then the DMF
was evaporated and the crude product was deprotected by reac-
tion with a trifluoroacetic acid/triisopropylsilane/water (TFA/
TIS/H2O; 95/2.5/2.5 v/v ratio) mixture (100 mL) for 2 hours at
room temperature. The crude product was then precipitated by
slow addition of diethyl ether, separated from the supernatant
by centrifugation, and dissolved in 30%MeCN/H2O. The crude
product was purified by preparative HPLC on a Macherey-
Nagel Nucleosil reverse phase C18 column (Oensingen, Ger-
many) with a 10% to 45%MeCN/H2O (0.1% TFA v/v added to
both solvents) gradient over 12 minutes. On this HPLC system,
the product eluted with a retention time (Rt) of 6.6 minutes. The
product was lyophilized to give compound 4 as a white amor-
phous powder (1.6 mg, 1.5 mmol, 16%). The (þ)-LR-ESI-MSm/
z (30%MeCN/H2O) 1076 (50%; [MþH]þ ¼ C47H84N10O182þ)
and 539 (100%; [Mþ2 H]2þ ¼ C47H84N10O182þ). The (þ)-HR-
ESI-MS m/z (30% MeCN/H2O) found 538.2981 (100%; [Mþ2
H]2þ) calculated for C47H84N10O18
2þ ¼ 538.2977.
Test labeling reactions conducted in water at room tempera-
ture using compound 4 and nonradioactive natGa(NO3)3 gave
the desired product natGa-DFO-Nsucc-PSMA (natGa-4) in solu-
tion, with a single peak in reverse-phase (RP) HPLC (10%-45%
MeCN/H2O gradient. Rt ¼ 10.2 minutes; >98%), (þ)-LR-ESI-
Figure 2. Coupling reactions used in the synthesis of desferrioxamine B (DFO)-Nsucc-prostate-specific membrane antigen (PSMA; compound
4) and DFO-pNCS-Bn-PSMA (compound 7).
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MS m/z (30%MeCN/H2O) 571 (100%; [Mþ2 H]2þ), (þ)-HR-
ESI-MS m/z (30%MeCN/H2O) found 571.2491 (100%; [Mþ2
H]2þ), calculated for C47H81N10O18Ga
2þ ¼ 571.2488. Addi-
tional test reactions labeling compound 4 with natFeCl3 gave an
instantaneous and intense color change from colorless to a deep
brown/orange solution, indicating the formation of an Fe-DFO
complex of orange/brown with a known broad electronic absorp-
tion maximum at 430 nm (e430 ¼ 2216+ 49 mol/dm3/cm).16
The DFO-pNCS-Bn-PSMA (7). Urea (6) was isolated by prepara-
tive HPLC after TFA/TIS/H2O deprotection of tris-tBu-
protected urea (3).19 Urea (6; 1.2 mg, MW 432.5 g mol-1, 2.8
mmol) was dissolved in DMF (250 mL). Separately, DFO-
pNCS-Bn (5; Macrocyclics, Dallas, Texas; 2.3 mg, MW
752.8 g/mol, 3.1 mmol, 1.1 equivalent) was dissolved in DMSO
(150 mL), and DIPEA (1.1 mL, 0.8 mmol, 2.2 equivalent) was
added. Then the solution of compound 5 was added to the
solution of compound 6, and the reaction was stirred for 24
hours at room temperature. Reaction progress was monitored
by (þ)-LR-ESI-MS. The crude reaction was then diluted with
2.1 mL H2O, and the product was purified by preparative HPLC
on a Macherey-Nagel Nucleosil reverse phase C18 column with
a 10% to 45% MeCN/H2O (0.1% TFA v/v added to both sol-
vents) gradient over 25 minutes. On this HPLC system, the prod-
uct eluted with a retention time Rt of 13.0 to 13.8 min. The
product was lyophilized to give compound 7 as a white amor-
phous powder (2.5 mg, 2.1 mmol, 76%). (þ)-LR-ESI-MS m/z
(50% MeCN/H2O) 1186 (30%; [MþH]þ ¼ C51H85N12O16S2þ)
and 594 (100%; [Mþ2 H]2þ ¼ C51H86N12O16S22þ), (þ)-HR-
ESI-MS m/z (50% MeCN/H2O) found 593.2877 (100%; [Mþ2
H]2þ) calculated for C51H86N12O16S2
2þ 593.2863.
Test labeling reactions conducted in water at room tempera-
ture using compound 7 and natGa(NO3)3 gave the desired prod-
uct natGa-DFO-pNCS-Bn-PSMA (natGa-7) in solution with a
single peak in RP-HPLC (10-45% MeCN/H2O gradient, Rt ¼
10.2 min; >98%), (þ)-LR-ESI-MS m/z (30%MeCN/H2O) 626
(100%; [Mþ2 H]2þ ¼ C51H83GaN12O16S22þ).
Radiochemistry
68Ga-radiolabeling experiments were conducted either manu-
ally or using the Modular-Lab PharmTracer automated synth-
esis module (Eckert&Ziegler, Berlin, Germany). Briefly, the
68Ge/68Ga-generator (Eckert&Ziegler, Model IGG100
Gallium-68 Generator) was eluted with HCl (0.1 M, 7 mL) in
accordance with the manufacturer’s protocol. The eluate
(*600 MBq) was loaded onto a cation exchange column
(Strata-XC [SCX]; Phenomenex, Torrance, California), and
68Ga was eluted from the SCX cartridge with 800 mL of a
mixture of 0.13 mol/L HCl in *5 mol/L NaCl(aq). For all
automated syntheses, the 68Ga eluate was transferred into the
reaction vial containing the appropriate buffer and radiolabel-
ing precursor (vide infra).
Radiosynthesis of 68Ga-HBED-CC-PSMA (68Ga-1). 68Ga-HBED-
PSMA (68Ga-1)19 was prepared in 10 minutes at 95C, using
the Modular-Lab PharmTracer module by Eckert & Ziegler
(Berlin, Germany). The 68Ga eluate (*600 MBq) was trans-
ferred into a preheated reaction vial containing sodium acetate
(2 mL, *1 mol/L, pH4.5), HCl (*0.18 mol/L), ascorbic acid
(20 mL, 100 mg/mL), and HBED-CC-PSMA (compound 1; 10
mg). The crude reaction mixture was loaded onto a SepPak
Light C-18 cartridge (Waters Corporation, Milford, Massachu-
setts) and then washed with water (10 mL) to remove uncom-
plexed radiometal ions and polar impurities. The radiotracer
was eluted in *0.5 mL 50% EtOH/H2O, and the product was
analyzed by RP-HPLC (Chromolith method: Rt ¼ 2.33 (25%)
and 2.38 (75%) min.; specific activity As ¼ 42.2 GBq/mmol).
Note two species (potentially diastereomers) are formed in an
approximate ratio of 1:3. These two species are shown to
behave in an identical manner toward PSMA binding in vitro
and in vivo.20 Typical decay-corrected radiochemical yields
(RCYs; including both species) were >98% (n ¼ 5) with radio-
chemical purity (RCP) >98% (n ¼ 5).
Radiosynthesis of 68Ga-DFO-Nsucc-PSMA (68Ga-4). 68Ga-DFO-
Nsucc-PSMA (68Ga-4) was prepared within 10 minutes at
room temperature by manual synthesis and using the
Modular-Lab PharmTracer module by Eckert & Ziegler (Ber-
lin, Germany). The 68Ga eluate (*600 MBq) was transferred
into a reaction vial containing ammonium acetate buffer (2.0
mL, 0.5 mol/L, pH5.2) and DFO-Nsucc-PSMA (compound 4;
10-20 mg). After reaction, the crude mixture was loaded onto a
SepPak Light C18 cartridge (Waters Corporation) and washed
with water (10 mL) to remove uncomplexed radiometal ions
and polar impurities. The radiotracer was eluted in *0.5 mL
30% EtOH/H2O, and the product was analyzed by RP-HPLC
(Chromolith method: Rt ¼ 2.39 min. (100%); specific activity
[As] ¼ 27.4 GBq/mmol). Typical decay-corrected RCYs were
>98% (n ¼ 8) with RCP >99% (n ¼ 8).
Radiosynthesis of 68Ga-DFO-pNCS-Bn-PSMA (68Ga-7). 68Ga-DFO-
pNCS-Bn-PSMA (68Ga-7) was prepared using the same proce-
dure describe for 68Ga-4 (vide supra). The 68Ga-7 radiotracer
was eluted from the Sep-Pak Light C18 cartridge in *0.5 mL
30% EtOH/H2O, and the product was analyzed by RP-HPLC
(Chromolith method: Rt ¼ 2.57-3.13 minutes (100%); As ¼
23.8 GBq/mmol). Typical decay-corrected RCYs were >96%
(n ¼ 8) with RCP >98% (n ¼ 8).
Lipophilicity (LogD) measurements
The lipophilicity values of the 68Ga-radiotracers are reported as
LogD (n-octanol/phosphate-buffered saline [PBS] pH7.4) and
were determined using the standard “shake-flask” method.39,40
Cells and Tissue Culture
The PSMA-positive LNCaP cells (ATCC, Manassas, Virginia)
were cultured at 37C in a 5% CO2 atmosphere (RPMI Medium
1640 GlutaMAX containing 1% fetal bovine serum [FBS], 100
U/mL penicillin, 100 mg/mL streptomycin, and sodium–pyru-
vate 1 mmol/L).
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Saturation Binding Experiments In Vitro
For receptor saturation analysis, PSMA(þ) LNCaP cells were
seeded at a density of 0.8 to 1 million cells per well in 6-well
poly-L-lysine (PLL)-coated plates and incubated overnight
with medium (RPMI Medium 1640 GlutaMAX containing
1% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and
1 mmol/L sodium pyruvate). After 24 hours, the medium was
removed, the cells were washed and incubated for 1 hour at
37C with fresh binding buffer (RPMI Medium 1640 Gluta-
MAX containing 1% FBS, 100 U/mL penicillin, 100 mg/mL
streptomycin, 50 mmol/L HEPES, 50 mg/mL bacitracin, and
0.5% bovine serum albumin). Then the plates were placed on
ice for 30 minutes, followed by incubation with increasing
concentrations of 68/natGa-radiotracers in PBS-binding buffer
(pH7.4) for 120 minutes at 4C. Nonspecific binding was deter-
mined in the presence of excess 2-(phosphonomethyl)pentane-
1,5-dioic acid (PMPA; 1 mmol/L). The cells were washed twice
with ice-cold PBS and then lysed with 1 mol/L NaOH. The
cell-associated radioactivity was measured using a gamma
counter. Specific binding was plotted against the total molar
concentration of the added radiotracer. The Kd/nM values and
the concentration of the radiotracers required to saturate the
receptors (Bmax/nM) were determined by nonlinear regression
analysis. In all cellular experiments, the calculated values were
normalized to the number of cells per well (typically 1  106
cells). Data reported are from 2 independent experiments with
triplicate data points in each experiment.
Xenograft Models
All animal experiments were conducted according to the reg-
ulations of the University Medical Center of Freiburg, Ger-
many, and in accordance with the principles of the 3Rs and
the Guide for the Care and Use of Laboratory Animals. Normal
athymic Balb/c nude mice (17-20 g, 4-6 weeks old, n ¼ 12)
were obtained from Janvier SAS (St Berthevin Cedex, France).
Mice were provided with food and water ad libitum. The
LNCaP tumors were induced on the right shoulder by subcu-
taneous (sc) injection of 5.0 million cells in a 100-mL cell
suspension of a 1:1 v/v mixture of media with reconstituted
basement membrane (GFR BD Matrigel; Corning BV, Amster-
dam, Holland). After an average of 4 weeks, the tumor size
reached*200 to 300 mg (estimated by caliper measurements),
and the animals were then used for PET imaging studies.
Blood Plasma Protein Binding Studies and Metabolism
In Vivo
Mice (n ¼ 2/group) were administered with appropriate for-
mulations of the 3 68Ga-radiotracers (7.3-11.1 MBq, 0.3-0.4
nmol in 0.2 mL PBS) via intravenous tail vein injections. Mice
were killed 15 minutes post-radiotracer administration. Blood
was collected in heparinized tubes and centrifuged (5 minutes,
1700 g) for plasma isolation. Plasma samples (300 mL) were
transferred to an ultrafiltration device (Vivacon 500; 30 kDa
molecular weight cutoff [Sartorius Stedium Biotech GmbH,
Germany]), and centrifuged (10 minutes, 9660 g) to separate
proteins. Samples of the filtrate and protein fraction were mea-
sured in the gamma counter. In addition, aliquots of the eluate
from ultrafiltration were analyzed by RP-HPLC to assess the
extent of radiotracer metabolism in the soluble blood
component.
Small-Animal PET Imaging
The PET imaging experiments were conducted on a micro-
PET Focus 120 scanner (Concorde Microsystems, Knoxville,
Tennessee).41 For static scans, mice were administered 68Ga-
radiotracer formulations (15.4-18.7 MBq, *0.56-0.68 nmol
in 200 mL sterile filtered PBS pH7.4 [Note: the ethanol con-
tent was <8% for all formulations]) via intravenous tail vein
injection. For dynamic scans, a higher dose of radioactivity
(*28 MBq, *0.9-1.0 nmol) was administered to ensure ade-
quate counting statistics during reconstruction of compara-
tively short timing windows (from between 20 seconds and
5 minutes). Approximately 5 minutes prior to recording PET
images, mice were anesthetized by inhalation of 2% to 3%
isoflurane/oxygen gas mixture, fitted with an intravenous
catheter (dynamic scans), and placed on the scanner bed in
the prone position. Anesthesia was maintained using 1% to
2% isoflurane. The PET images were recorded at various time
points between 0 and 3 hours postinjection. Dynamic scans
were recorded for 3500 seconds postradiotracer administra-
tion and temperature was maintained using a heating pad.
List-mode data were acquired using a g-ray energy window
of 350 to 650 keV and a coincidence timing window of 6
nanoseconds. The PET sinograms were reconstructed using
a 2-dimensional ordered subset expectation maximization
algorithm. Image counts per second per voxel were calibrated
to activity concentrations (Bq/g) by measuring a 3.5-cm cylin-
der phantom filled with a known concentration of radioactiv-
ity and mass. For quantification of tumor radioactivity uptake
in the PET scans, small 3-dimensional volumes-of-interest
(VOIs) were drawn manually using AMIDE Medical Image
Data Examiner software,42 and the decay corrected mean per-
centage injected dose per gram (%ID/g) in various tissues was
determined.
Competitive inhibition (blocking) studies were also per-
formed in vivo using static PET imaging to investigate the
specificity of the 68Ga-radiotracers for PSMA. Non-
radiolabeled PMPA (20 nmol/mouse) was coinjected with the
68Ga-radiotracers (n ¼ 3).43
Statistical Analyses
Statistical analyses were performed using GraphPad Prism 5.01
(GraphPad Software, Inc, San Diego, California) and Microsoft
Excel (Version 15). Data were analyzed using the unpaired, 2-
tailed Student t test. Differences at the 95% confidence level (P
< .05) were considered to be statistically significant.
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Results and Discussion
Synthesis and Radiochemistry
Ligands 4 and 7 were synthesized using standard amide bond or
thiourea chemistries in 16% and 76% yield, respectively. A
summary of the in vitro characterization data is presented in
Table 1. Both compounds gave single peaks in RP-HPLC with
>98% chemical purity. The chemical composition of com-
pounds 4 and 7 was confirmed using both low- and high-
resolution electrospray ionization mass spectrometry. For
compounds 4 and 7, peaks corresponding to the monoproto-
nated molecular ion [MþH]þ and the diprotonated species
[Mþ2 H]2þ were identified in (þ)-LR-ESI-MS. In (þ)-HR-
ESI-MS only peaks corresponding to the [Mþ2 H]2þ ions (at
m/z 538.2981 and 593.2877, for 4 and 7, respectively) were
found. Subsequent nonradioactive reactions between ligands
4 and 7 with Ga(NO3)3 gave the expected peaks at m/z 571 and
626 (100%; [Mþ2 H]2þ), respectively. Furthermore, a test
reaction between an aqueous solution of ligand 4 and FeCl3
gave an instantaneous color change from colorless to an intense
orange/brown, confirming the formation of the Fe-DFO com-
plex. Note that Fe-DFO has a known broad electronic absorp-
tion maximum at 430 nm.16
Manual and fully automated 68Ga-radiolabeling reactions
were optimized in ammonium acetate buffer (0.5 mol/L, pH
5.2, room temperature). 68Ga-radiolabeling of 4 and 7 pro-
ceeded quantitatively at room temperature in 10 to 15 minutes.
Both radiolabeled compounds 68Ga-4 and 68Ga-7 were isolated
from the reaction mixture using a Sep-Pak Light C18 cartridge
(Waters Corporation, Milford, MA). After loading the C18
cartridge, the compounds were purified from unreacted 68Ga3þ
ions by washing with water or saline, and the product was
eluted with 20% to 30% EtOH/water (v/v). The average RCYs
for 68Ga-4 and 68Ga-7 were >98% (n ¼ 8) and >96% (n ¼ 8),
with RCP >98%, and specific activities of 27.4 and 23.8 GBq/
mmol, respectively. In comparison, using a similar automated
synthesis module, 68Ga-1 was isolated with an As of 42.2 GBq/
mmol. Notably, when higher amounts of initial 68Ga-
radioactivity are used in the routine clinical preparation of
68Ga-1, Ass as high as 75 to 80 GBq/mmol can be achieved.
When the initial amount of labeling precursors 4 and 7 was
reduced from 20 mg to 10 mg, Ass of
68Ga-4 and 68Ga-7
increased accordingly and were comparable to that attained for
68Ga-1. Both radiolabeled compounds 68Ga-4 and 68Ga-7 were
found to be stable with respect to changes in RCP after
incubation in saline or PBS at 37C for over 4 hours. These
data confirmed that no radiolysis or chemical degradation
occurred in the formulated samples used for in vitro and in
vivo studies.
Lipophilicity measurements for 68Ga-1, 68Ga-4, and 68Ga-7
gave LogD values of 4.06+ 0.10, 3.24+ 0.05, and 2.60
+ 0.02, respectively. In comparison to 68Ga-1, the new DFO-
conjugated compounds are less hydrophilic. Consistent with
the chemical structures of the linker groups, measurements
showed that the more hydrophilic succinyl linker/spacer in
68Ga-4 conveys increased water solubility compared to the
aromatic pNCS-Bn group in 68Ga-7.
Cellular Assays
Prior to conducting PET imaging in mice, the cellular dissocia-
tion constants (Kd/nM) and specificity of
68/natGa-radiotracers
1, 4, and 7 were measured using standard saturation binding
experiments in LNCaP PSMA(þ) cells (Table 1 and Figure
S1).16,44,45 Across all experiments, estimated receptor concen-
trations (Bmax values) were consistent in the range 0.27 to 0.41
nmol/L. Cellular binding data confirmed that both 68Ga-
radiotracers of ligands 4 and 7 bind specifically to PSMA
expressed on LNCaP cells. The apparent Kd values of
68Ga-4
(26.4 + 7.8 nmol/L) and 68Ga-7 (13.6 + 2.6 nM) indicate that
these compounds exhibit lower affinity toward PSMA than the
current clinical radiotracer 68Ga-7 (2.89+ 0.55 nmol/L). Typi-
cally, a lower binding affinity of a radiotracer would reduce
target tissue uptake in PET imaging. However, it is worth not-
ing that specific contrast in PET is influenced by multiple
factors including nonspecific uptake, tissue perfusion, cellular
internalization, and sequestration which influences retention/
washout, metabolic stability, and whole-body excretion. There-
fore, PET imaging in tumor-bearing mice was performed to
evaluate radiotracer pharmacokinetics.
Positron-Emission Tomography Imaging in
Tumor-Bearing Mice
A combination of dynamic (for 3500s) and static PET scans
(starting at 30 minutes, 1, 2, and 3 hours postradiotracer admin-
istration) were used to assess the pharmacokinetics and speci-
ficity of the 68Ga-radiotracers for detecting PSMA expression
in mice bearing subcutaneous LNCaP tumors on the right
shoulder. Representative static PET images recorded at 1 hour
Table 1. Summary of the In Vitro Characterization Data.
Compound Molecular Formula MW (calcd) /g/mola Specific activity / GBq/mmol LogD (n-octanol: PBS pH7.4) Kd / nmol/L
68Ga-1 C44H58GaN6O17S2
– 1075.2561 42.2 4.06+ 0.10 2.89+ 0.55
68Ga-4 C47H79GaN10O18 1140.4830 27.4 3.24+ 0.05 26.4+ 7.8
68Ga-7 C51H81GaN12O16S2 1250.4591 23.8 2.60+ 0.02 13.6+ 2.6
Abbreviations: 68Ga-1, 68Ga-HBED-CC-PSMA; 68Ga-4, 68Ga-DFO-Nsucc-PSMA; 68Ga-768, Ga-DFO-pNCS-Bn-PSMA; PSMA, prostate-specific membrane
antigen.
aExact isotopic mass.
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are shown in Figure 3. Additional PET data are presented in
Supporting Information Figures S2 to S6. Competitive inhibi-
tion studies (blocking using coadministration of PMPA [20
nmol/mouse]43) confirmed the specificity of the 68Ga-
radiotracers for PSMA expression. Time–activity curves
(TACs) of the tumor, heart/blood pool, kidney, and bladder
measured from VOI analysis of the dynamic PET data are
shown in Figure 4.
Imaging data revealed that the 2 radiotracers, 68Ga-4 and
68Ga-7, showed specific accumulation in PSMA(þ) LNCaP
tumors. In the case of 68Ga-4, peak uptake (*3-4%ID/g) was
observed within the first 5 to 10 minutes postadministration,
after which, rapid washout of the radioactivity occurred. The
tumor washout phase for 68Ga-4 correlated with decreased
activity in the heart/blood pool and excretion via the kidneys/
bladder (Figure 4). At later time points (1-3 hours), 68Ga-4
tumor uptake/retention showed higher accumulation in tumors
than the background due to perfusion (Figures S3 and S4).
However, after 3 hours postadministration, absolute tumor
uptake of 68Ga-4 remained very low (*0.8-1.2%ID/g).
In dynamic PET, 68Ga-7 showed similar peak tumor uptake
(*3.5-4.0%ID/g) to 68Ga-4 but overall had a dramatically dif-
ferent pharmacokinetic profile. Heart/blood pool activity of
68Ga-7 remained higher at each time point in the dynamic
scans, and in contrast to the rapid tumor washout observed for
68Ga-4, tumor-associated radioactivity showed slower washout
for 68Ga-7 (2.90 + 0.46%ID/g after 3500 seconds). Static PET
imaging revealed that tumor-associated 68Ga-7 activity was
specific and retained at *2.5-3.5%ID/g for up to 3 hours (Fig-
ures S5 and S6 [blocking study]).
Equivalent dynamic and static PET imaging experiments
using the standard clinical agent 68Ga-1 showed that this radio-
tracer has a longer residence time in the heart/blood pool, with
considerably higher uptake and retention of radioactivity in
both the LNCaP tumors and in the kidneys (Figure 4 and Figure
S2). In dynamic scans, 68Ga-1 tumor uptake continued to
increase to >8.0%ID/g after 3500 seconds.
Interestingly, the 3 68Ga-radiotracer studied displayed com-
pletely different pharmacokinetic uptake/excretion profiles
(see heart/blood pool, kidney and bladder TACs in Figure 4).
The TACs showed that each of the 68Ga-radiotracers was
extracted from the blood. However, 68Ga-4 was most rapidly
cleared from circulation, followed by 68Ga-7 and then 68Ga-1.
Clearance is predominantly via a urinary mechanism, and the
radiotracers showed specific binding to the kidney (which is
known to express PSMA). Kidney TACs confirmed the differ-
ences in the behavior of the 3 68Ga-radiotracers (Figure 4C).
Specifically, 68Ga-4 showed a very rapid influx and efflux from
the kidney, concordant with low affinity binding to PSMA and
a rapid clearance to the bladder. In contrast, 68Ga-7 displayed a
broader and more prolonged residence in the kidney tissue with
a peak uptake of *50%ID/g at *1400 seconds postadminis-
tration followed by a slow washout phase. The clinical radio-
tracer, 68Ga-1, displayed rapid accumulation in the kidney with
a maximum around 30%ID/g at*500 seconds postadministra-
tion which was retained for the duration of the dynamic scans.
Figure 3. Representative static positron emission tomography (PET) scans of 68Ga-HBED-CC- prostate-specific membrane antigen (PSMA)-
(68Ga-1), 68Ga- desferrioxamine B (DFO)-Nsucc-PSMA (68Ga-4), and 68Ga-DFO-pNCS-Bn-PSMA (68Ga-7) recorded at 1 hour postradio-
tracer administration in mice bearing subcutaneous LNCaP tumors (*200-300 mg). In each case, blocking studies confirmed the specificity of
the 68Ga-radiotracer for PSMA expression. Note that in the 3 sets of image data, different upper thresholds (in units of %ID/g) have been used
for visual clarity in the representation of radiotracer uptake in the tumors. T indicates tumor; K, kidney; B, bladder.
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Pharmacokinetic profiles of 68Ga-1 in kidney and bladder are
consistent with rapid and specific binding of the radiotracer to
the available PSMA. The TAC data suggest that after *500
seconds postradiotracer administration of 68Ga-1, an equili-
brium is reached between uptake and clearance in the kidney.
Bladder TACs are consistent with conclusion Figure 4D. The
tumor uptake, kidney binding, and bladder excretion profiles of
68Ga-1, 68Ga-4, and 68Ga-7 are consistent with the measured
cellular dissociation constants (Kd values; Table 1).
Plasma Protein Binding and Metabolic Stability
To address differences in the pharmacokinetic profiles
observed for the 3 68Ga-radiotracer, ex vivo plasma protein
binding and metabolite analyses were conducted using size-
exclusion and HPLC methods. Radiotracers were injected into
groups of mice and blood samples (n ¼ 2/radiotracer) were
taken at 15 minutes postradiotracer administration. Plasma pro-
teins were separated from the soluble component by ultrafiltra-
tion and radioactivity counted (Figure 5A). These data revealed
that 68Ga-1 had the highest degree of protein association (92%
+ 4%), followed by 68Ga-7 (86% + 2%) and then 68Ga-4
(82%+ 7%). Statistical analysis revealed that protein binding
of 68Ga-1 was significantly different (P value <.05) when com-
pared to that of 68Ga-4 and 68Ga-7. Differences between pro-
tein binding of 68Ga-4 and 68Ga-7 were not statistically
significant (P value >.05). These data are consistent with the
heart/blood pool TACs in that increased protein binding corre-
lates with longer blood pool circulation (and consequently,
increased delivery and uptake in the LNCaP tumors).
The HPLC analysis of the radioactivity in the soluble frac-
tion of the blood pool revealed that both 68Ga-4 and 68Ga-7
remained 100% intact and chemically unchanged after 15 min-
utes in mice (Figure 5B). Chemical identity was confirmed by
comparison (and spiking) with the isolated 68Ga-4 and 68Ga-7
radiotracers. Similar to reported data for 68Ga-1, these data
demonstrated that 68Ga-4 and 68Ga-7 are metabolically stable
in mice.19,20 Therefore, differences in the tumor uptake, PSMA
binding, and pharmacokinetics are not associated with radio-
active metabolites.
The PET imaging and ex vivo data provide compelling evi-
dence for the stability, sensitivity, and specificity of these urea-
Figure 4. Time–activity curves (TACs) of the accumulation and washout of 68Ga-radioactivity in (A) the tumor, (B) the heart/blood pool, (C)
the kidneys, and (D) the bladder from 0 to 30 minutes postadministration of 68Ga-HBED-CC-PSMA (68Ga-1; black), 68Ga-desferrioxamine B
(DFO)-Nsucc-PSMA (68Ga-4; blue), and 68Ga-DFO-pNCS-Bn-PSMA (68Ga-7; red).
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based inhibitors for detecting PSMA expression. It is notable
that PSMA binding and pharmacokinetics are both highly sen-
sitive toward changes in the structure of the radiotracer (includ-
ing the chelate, linker, and spacer used to couple the nuclide to
the targeting moiety). These data highlight the importance of
the chelate and of optimizing all components of a biological
targeting construct to achieve the specific contrast.
Conclusion
Two anti-PSMA urea-based radiotracers incorporating DFO as
a chelate for coordinating 68Ga3þ ions have been synthesized,
radiolabeled, and evaluated in a series of in vitro and in vivo
experiments. Radiolabeling studies found that 68Ga3þ can be
complexed efficiently and rapidly at room temperature using
manual or automated methods that yield formulated radiotra-
cers (68Ga-4 and 68Ga-7) in high yields, purity, and specific
activity suitable for PET imaging. In contrast to the radiosynth-
esis of the clinical standard 68Ga-1, the use of DFO as a chelate
instead of HBED for 68Ga radiolabeling gives products with a
single peak in HPLC. Cellular data (Kd values) showed that
68Ga-4 and 68Ga-7 displayed lower affinity for PSMA
expressed on LNCaP cells than 68Ga-1. Dynamic and static
PET scans also revealed important differences in the pharma-
cokinetic profiles of the 3 68Ga-radiotracers. Each radiotracer
showed specific binding and high delineation of PSMA-
positive LNCaP tumors. However, in comparison to 68Ga-1,
absolute uptake values in the tumor were *10-fold and
*2.5-fold lower for 68Ga-4 and 68Ga-7, respectively. In addi-
tion, blood pool clearance, kidney retention, and urinary excre-
tion profiles were altered dramatically by changing the chelate
and linker/spacer groups. Clearance profiles were found to
correlate with both plasma protein binding and measured cel-
lular dissociation constants (Kd values) but not with complex
lipophilicity (LogD values). Collectively, these data demon-
strate that PSMA binding of small-molecule urea-based
inhibitors is particularly sensitive to changes in the entire
chemical structure from the targeting moiety, through to the
spacer group, linker, and chelate (and likely the chemical
nature of the radionuclide) employed in radiotracer design.
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